Beyondspring (BYSI) Stock Price

Beyondspring Price

NASDAQ·CLOSED
0.72USD-0.0001 (-0.01 %)
Market closed

Revenue has compounded at 174.0% per year over the past 2 years to 1.35 M USD. Beyondspring's net margin stands at -2,463.3%, up from -33,873.9% several years earlier. Analysts set a median price target of 1.28 USD, implying 77.1% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 1% above its 52-week low.

Beyondspring stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Beyondspring over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Beyondspring stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Beyondspring's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Beyondspring Stock Price History
DateBeyondspring Price
8/24/20260.72 USD
8/21/20260.72 USD
8/20/20260.72 USD
8/19/20260.75 USD
8/18/20260.71 USD
8/17/20260.71 USD
8/14/20260.84 USD
8/13/20261.00 USD
8/12/20260.79 USD
8/10/20260.79 USD
8/7/20260.87 USD
8/6/20260.87 USD
8/5/20260.98 USD
8/4/20261.05 USD
8/3/20261.17 USD
7/31/20261.15 USD
7/30/20261.13 USD
7/29/20261.17 USD
7/27/20261.16 USD
7/23/20261.08 USD
7/22/20261.13 USD
7/21/20261.25 USD
7/20/20261.24 USD
7/17/20261.29 USD
7/16/20261.28 USD
7/15/20261.27 USD
7/14/20261.33 USD
7/13/20261.41 USD
7/10/20261.44 USD
7/9/20261.49 USD
7/8/20261.62 USD
7/7/20261.66 USD
7/6/20261.78 USD
7/2/20261.87 USD
7/1/20261.85 USD
6/30/20261.75 USD
6/29/20261.79 USD
6/26/20261.69 USD
6/25/20261.60 USD
6/24/20261.64 USD
6/23/20261.61 USD
6/22/20261.57 USD
6/18/20261.61 USD
6/17/20261.59 USD
6/16/20261.60 USD
6/15/20261.65 USD
6/12/20261.57 USD
6/11/20261.65 USD
6/10/20261.65 USD
6/9/20261.72 USD
6/8/20261.70 USD
6/5/20261.71 USD
6/4/20261.71 USD
6/3/20261.74 USD
6/2/20261.70 USD
6/1/20261.74 USD
5/29/20261.68 USD
5/28/20261.72 USD
5/27/20261.71 USD
5/26/20261.54 USD
5/22/20261.57 USD
5/21/20261.44 USD
5/20/20261.44 USD
5/19/20261.29 USD
5/18/20261.39 USD
5/15/20261.36 USD
5/14/20261.50 USD
5/13/20261.45 USD
5/12/20261.39 USD
5/11/20261.52 USD
5/8/20261.49 USD
5/7/20261.42 USD
5/6/20261.55 USD
5/5/20261.44 USD
5/4/20261.51 USD
5/1/20261.49 USD
4/30/20261.52 USD
4/29/20261.47 USD
4/28/20261.51 USD
4/27/20261.56 USD
4/24/20261.71 USD
4/23/20261.66 USD
4/22/20261.63 USD
4/21/20261.74 USD
4/20/20261.78 USD
4/17/20261.73 USD
4/16/20261.68 USD
4/15/20261.69 USD
4/14/20261.73 USD
4/13/20261.75 USD
4/10/20261.74 USD
4/9/20261.77 USD
4/8/20261.76 USD
4/7/20261.72 USD
4/6/20261.71 USD
4/2/20261.73 USD
4/1/20261.71 USD
3/31/20261.64 USD
3/30/20261.62 USD
3/27/20261.60 USD
3/26/20261.61 USD
3/25/20261.68 USD
3/24/20261.62 USD
3/23/20261.65 USD
3/20/20261.60 USD
3/19/20261.56 USD
3/18/20261.79 USD
3/17/20261.79 USD
3/16/20261.74 USD
3/13/20261.69 USD
3/12/20261.63 USD
3/11/20261.51 USD
3/10/20261.47 USD
3/9/20261.48 USD
3/6/20261.45 USD
3/5/20261.49 USD
3/4/20261.54 USD
3/3/20261.55 USD
3/2/20261.37 USD
2/27/20261.35 USD
2/26/20261.30 USD
2/25/20261.30 USD
2/24/20261.36 USD
2/23/20261.29 USD
2/20/20261.30 USD
2/19/20261.32 USD
2/18/20261.32 USD
2/17/20261.30 USD
2/13/20261.27 USD
2/12/20261.37 USD
2/11/20261.42 USD
2/10/20261.49 USD
2/9/20261.51 USD
2/6/20261.50 USD
2/5/20261.54 USD
2/4/20261.57 USD
2/3/20261.51 USD
2/2/20261.56 USD
1/30/20261.54 USD
1/29/20261.56 USD
1/28/20261.55 USD
1/27/20261.61 USD
1/26/20261.58 USD
1/23/20261.62 USD
1/22/20261.67 USD
1/21/20261.67 USD
1/20/20261.70 USD
1/16/20261.71 USD
1/15/20261.77 USD
1/14/20261.67 USD
1/13/20261.63 USD
1/12/20261.66 USD
1/9/20261.59 USD
1/8/20261.59 USD
1/7/20261.53 USD
1/6/20261.50 USD
1/5/20261.51 USD
1/2/20261.61 USD
12/31/20251.63 USD
12/30/20251.71 USD
12/29/20251.82 USD
12/26/20251.84 USD
12/24/20251.92 USD
12/23/20251.86 USD
12/22/20251.90 USD
12/19/20252.35 USD
12/18/20251.87 USD
12/17/20251.90 USD
12/16/20251.98 USD
12/15/20251.99 USD
12/12/20252.11 USD
12/11/20252.18 USD
12/10/20252.02 USD
12/9/20251.94 USD
12/8/20251.98 USD
12/5/20251.99 USD
12/4/20251.93 USD
12/3/20251.90 USD
12/2/20251.97 USD
12/1/20252.01 USD
11/28/20252.12 USD
11/26/20252.09 USD
11/25/20251.98 USD
11/24/20251.87 USD
11/21/20251.92 USD
11/20/20251.74 USD
11/19/20251.95 USD
11/18/20251.95 USD
11/17/20252.05 USD
11/14/20252.09 USD
11/13/20252.06 USD
11/12/20252.12 USD
11/11/20252.20 USD
11/10/20251.93 USD
11/7/20251.96 USD
11/6/20251.92 USD
11/5/20251.95 USD
11/4/20252.02 USD
11/3/20252.07 USD
10/31/20251.99 USD
10/30/20251.91 USD
10/29/20251.83 USD
10/28/20251.85 USD
10/27/20251.87 USD
10/24/20252.01 USD
10/23/20252.02 USD
10/22/20252.04 USD
10/21/20252.20 USD
10/20/20251.74 USD
10/17/20251.77 USD
10/16/20251.79 USD
10/15/20251.65 USD
10/14/20251.64 USD
10/13/20251.71 USD
10/10/20251.74 USD
10/9/20251.81 USD
10/8/20251.79 USD
10/7/20251.80 USD
10/6/20251.78 USD
10/3/20251.75 USD
10/2/20251.73 USD
10/1/20251.79 USD
9/30/20251.81 USD
9/29/20251.74 USD
9/26/20251.76 USD
9/25/20251.68 USD
9/24/20251.69 USD
9/23/20251.66 USD
9/22/20251.79 USD
9/19/20251.92 USD
9/18/20251.72 USD
9/17/20251.79 USD
9/16/20251.90 USD
9/15/20251.87 USD
9/12/20251.82 USD
9/11/20251.87 USD
9/10/20251.91 USD
9/9/20251.94 USD
9/8/20251.90 USD
9/5/20251.86 USD
9/4/20251.84 USD
9/3/20251.82 USD
9/2/20251.83 USD
8/29/20251.72 USD
8/28/20251.80 USD
8/27/20251.82 USD
8/26/20251.77 USD
Access this data via the Eulerpool API
Get Free API Key

Beyondspring Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
0.00 USD
-57.55 M USD
-54.87 M USD
Jan 1, 2019
0.00 USD
-40.31 M USD
-38.09 M USD
Jan 1, 2020
180,000.00 USD
-64.21 M USD
-60.97 M USD
Jan 1, 2021
1.35 M USD
-66.24 M USD
-64.18 M USD
Jan 1, 2022
1.35 M USD
-37.24 M USD
-33.28 M USD
Jan 1, 2023
0.00 USD
-15.08 M USD
-21.03 M USD
Jan 1, 2024
0.00 USD
-8.75 M USD
-11.12 M USD
Jan 1, 2025 (e)
1.34 M USD
-45.88 M USD
-42.73 M USD

Beyondspring Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 3:34 PM
 
REVENUEk USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201420152016201720182019202020212022202320242025e
–––––––1,000.001,000.00––1,000.00
-2.00-7.00-12.00-97.00-57.00-40.00-64.00-66.00-37.00-15.00-8.00-45.00
–––––––-6,600.00-3,700.00––-4,500.00
-3.00-7.00-12.00-91.00-54.00-38.00-60.00-64.00-33.00-21.00-11.00-42.00
–133.3371.43658.33-40.66-29.6357.896.67-48.44-36.36-47.62281.82
13.9115.1716.0920.8722.6724.6529.9839.0239.0939.0039.7339.73
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Beyondspring generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Beyondspring retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Beyondspring's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Beyondspring has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Beyondspring's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Beyondspring stock margins

The Beyondspring margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Beyondspring. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Beyondspring.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
0.00 %
- %
- %
Jan 1, 2019
0.00 %
- %
- %
Jan 1, 2020
0.00 %
-35,672.78 %
-33,873.89 %
Jan 1, 2021
0.00 %
-4,903.04 %
-4,750.48 %
Jan 1, 2022
0.00 %
-2,756.40 %
-2,463.29 %
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025 (e)
0.00 %
-3,429.32 %
-3,193.95 %

Beyondspring Stock Revenue, EBIT, Earnings per Share

The Beyondspring earnings per share therefore indicates how much revenue Beyondspring has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 USD
-2.54 USD
-2.42 USD
Jan 1, 2019
0.00 USD
-1.64 USD
-1.55 USD
Jan 1, 2020
0.01 USD
-2.14 USD
-2.03 USD
Jan 1, 2021
0.03 USD
-1.70 USD
-1.64 USD
Jan 1, 2022
0.03 USD
-0.95 USD
-0.85 USD
Jan 1, 2023
0.00 USD
-0.39 USD
-0.54 USD
Jan 1, 2024
0.00 USD
-0.22 USD
-0.28 USD
Jan 1, 2025 (e)
0.03 USD
-1.15 USD
-1.08 USD

Beyondspring business model & stock analysis

Beyondspring Inc is a globally operating biopharmaceutical company dedicated to the development of innovative cancer drugs. The company was founded in 2014 in New York City and today Beyondspring is based in New York and Shanghai. The founding of Beyondspring aimed to bring innovative cancer therapies to market that provide better treatment outcomes for patients. The company particularly focuses on a combination of proven therapeutic approaches and innovative technology, aiming to take a leading role in the oncology industry. Beyondspring focuses on the development of highly effective cancer therapies based on two platform technologies: protein engineering and immuno-oncology. The company is searching for substances that can strengthen the body's immune system and attack cancer cells. At the core of its business operations is the product Plinabulin. This is a novel cyclic peptide drug that is capable of activating the immune system and destroying cancer cells. The drug has been tested in multiple clinical trials and has shown promising results, particularly in breast cancer and lung cancer. In addition to product development, Beyondspring is also involved in the market development and commercialization of cancer drugs. The company works closely with hospitals, doctors, and other healthcare stakeholders to promote the use of Plinabulin and improve patient care. Beyondspring specializes in various types of cancer, such as lung cancer, breast cancer, and leukemia, where Plinabulin can be used. The company strives to constantly expand its product portfolio to explore additional indications. Beyondspring's business model relies on close collaboration with industry partners and the establishment of a global network. The company collaborates with leading research institutions and universities and continuously invests in the development of innovative technologies. The goal of Beyondspring is to provide cancer patients worldwide with access to innovative and highly effective treatment options. To achieve this, the company collaborates with regulatory authorities to expedite the approval of new drugs. Overall, Beyondspring is characterized by a highly dynamic and future-oriented business model. With its focus on innovative cancer therapies and the continuous expansion of its portfolio, the company has already established a strong position in the industry. In the future, Beyondspring will continue to expand its global presence and broaden its product range to provide cancer patients with the best possible treatment outcomes.

Beyondspring SWOT Analysis

Strengths

Beyondspring Inc has several strengths that contribute to its success. Firstly, the company possesses a strong pipeline of innovative drugs, which provide opportunities for growth and expansion. Additionally, the company has a highly skilled and experienced management team that possesses deep expertise in the biopharmaceutical industry. This enables Beyondspring Inc to effectively navigate complex regulatory processes and drive strategic decision-making.

Weaknesses

Despite its strengths, Beyondspring Inc also faces certain weaknesses that could hinder its growth. One major weakness is the company's heavy reliance on a limited number of drug candidates in its pipeline. This concentration of resources and risks exposes the company to potential setbacks if any of these candidates fail to receive approval or encounters unforeseen challenges. Moreover, the company's geographical presence is currently limited, which may restrict its market reach and impact its competitive position.

Opportunities

Beyondspring Inc has various opportunities in the biopharmaceutical space. The increasing global demand for innovative cancer treatments presents a significant opportunity for the company to capitalize on its pipeline of novel drugs. Furthermore, potential partnerships and collaboration with other industry players can help expand the company's market access and accelerate drug development. Moreover, advancements in technology and personalized medicine offer opportunities for Beyondspring Inc to develop tailored treatments, enhancing patient outcomes.

Threats

Alongside opportunities, Beyondspring Inc faces threats that could impact its performance. One significant threat is intense competition from both established pharmaceutical companies and emerging biotech firms. This competition can challenge the company's ability to secure market share and capture a significant patient population. Additionally, uncertainties surrounding regulatory policies and approvals pose a threat, as changes in regulations can impact drug development timelines and overall market conditions. Moreover, potential adverse events or safety concerns associated with the company's drugs could lead to reputational damage and loss of investor confidence.

Beyondspring Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Beyondspring historical P/E ratio, EBIT multiple, and P/S ratio

Beyondspring annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Beyondspring shares outstanding

The number of shares of Beyondspring was 39.73 M in 2025. This indicates how many shares Beyondspring is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
22.67 M Stocks
Jan 1, 2019
24.65 M Stocks
Jan 1, 2020
29.98 M Stocks
Jan 1, 2021
39.02 M Stocks
Jan 1, 2022
39.09 M Stocks
Jan 1, 2023
39.00 M Stocks
Jan 1, 2024
39.73 M Stocks
Jan 1, 2025 (e)
39.73 M Stocks

Current Beyondspring forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
1.28
Last Price
0.72
Currency
USD
12M Return Potential
77.11 %
LTM Return
0 %

Beyondspring Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
4/12/2023-0.29USD-395,849.00USD-2022 Q4
11/29/2022-0.23USD-345,099.00USD-2022 Q1
11/14/2022-0.23USD-345,099.00USD-2022 Q3
11/1/2022-0.24USD-345,099.00USD-2022 Q2
4/14/2022-0.27USD-7.75 MUSD-2021 Q4
12/30/2021-0.38USD-9.20 MUSD-2021 Q3
9/10/2021-0.33USD-8.90 MUSD-2021 Q2
6/16/2021-0.55USD-0.00USD-2021 Q1
4/30/2021-0.46USD-0.00USD-2020 Q4
11/17/2020-0.55USD-0.00USD-2020 Q3

EESG©

Eulerpool ESG Scorecard© for the Beyondspring stock

57/100
53
Environment
38
Social
81
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Beyondspring shareholder structure

% Name
10.57209%
Decheng Capital LLC
Decheng Capital LLC

Beyondspring Executives and Management Board

7 members · avg. age 55 · 43 % women

LH

Dr. Lan Huang (54)

Chairperson of the Board, Chief Executive Officer, Co-Founder · since 2014

793,432.00 USD

Management

JL

Dr. June Lu (59)

Chief Scientific Officer

497,972.00 USD

Board of Directors

MK

Mr. Matthew Kirkby (56)

Independent Director

71,400.00 USD
PF

Mr. Patrick Fabbio (57)

Independent Director

63,400.00 USD
JM

Dr. Jiangwen Majeti (57)

Independent Director

61,400.00 USD
BD

Mr. Brendan Delaney (50)

Independent Director

55,400.00 USD
SX

Mr. Sihai Xu (53)

Director

47,400.00 USD

Beyondspring Supply Chain

Beyondspring Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
6 companies
#NameTrend
1
Johnson Matthey
Supplier·Customer·Chemicals·GB
-0.17
-0.28
-0.46
0.73
0.74
0.52
#NameTrend
1
Eli Lilly
Supplier·Customer·Pharmaceuticals·US
-0.76
0.71
-0.49
-0.22
-0.28
-0.33
2
ICON
Supplier·Life Sciences Tools & Services·IE
0.04
0.77
0.63
0.53
0.09
-0.19
3
AllianceBernstein Holding
Supplier·Customer·Capital Markets·US
-0.41
0.79
0.62
0.74
0.59
-0.09
4
Eurofins Scientific
Supplier·Life Sciences Tools & Services·LU
0.45
0.82
0.04
0.66
0.79
0.09
5
BASF
Supplier·Chemicals·DE
0.53
0.33
0.75
0.26
0.47
0.10

Frequently asked questions about Beyondspring

The business model of Beyondspring Inc revolves around the development and commercialization of innovative immuno-oncology drugs. They focus on creating new treatment options for patients with high unmet medical needs, particularly in the areas of cancer and inflammatory diseases. Beyondspring Inc aims to leverage their expertise in immuno-oncology, research, and development, alongside strategic partnerships, to advance their drug candidates and bring them to market. Their commitment to improving patient outcomes and addressing critical medical challenges drives their business approach and guides their efforts in developing cutting-edge therapies for the benefit of individuals worldwide.

Beyondspring Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Beyondspring Inc in the market include companies such as Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, and Merck & Co., Inc.

Beyondspring Inc. is a biopharmaceutical company focused on the development of innovative cancer therapies. Founded in 2012 and headquartered in New York, the company is dedicated to improving the lives of patients by advancing its extensive pipeline of promising drug candidates. Beyondspring Inc. specializes in the development of innovative immuno-oncology drugs and novel targeted therapies. With a strong team of experienced professionals and strategic partnerships, the company is committed to bringing new treatment options to patients suffering from serious and life-threatening illnesses. Beyondspring Inc. continues to grow and make significant advancements in the field of cancer therapeutics.

Beyondspring Inc has achieved several significant milestones that have propelled the company's growth and success. Notably, the company successfully completed Phase 3 clinical trials for its lead product, Plinabulin, as a potential breakthrough in chemotherapy-induced neutropenia. Beyondspring Inc also obtained Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for Plinabulin, expanding its potential market reach and driving investor confidence. Moreover, the company forged key partnerships and collaborations with renowned institutions to further advance its innovative pipeline and enhance its market position. These achievements highlight Beyondspring Inc's commitment to delivering cutting-edge solutions and positioning itself as a leader in the biopharmaceutical industry.

Beyondspring Inc is primarily present in the United States and China.

Beyondspring Inc is a leading pharmaceutical company that is committed to transforming the lives of patients through innovative and cutting-edge medical solutions. The company's corporate philosophy revolves around scientific excellence, patient-centricity, and integrity. Beyondspring Inc firmly believes in developing groundbreaking therapies that address unmet medical needs and improve patient outcomes. By fostering a culture of innovation and collaboration, the company aims to revolutionize the field of oncology and provide hope to patients around the world. Beyondspring Inc's dedication to advancing medical breakthroughs reflects their commitment to delivering value and making a positive impact in the healthcare industry.

Analysts currently set an average price target of 1.28 USD for the Beyondspring stock (median: 1.28 USD), implying +77.1 % versus the latest price. The consensus is based on 7 analyst ratings.

Beyondspring Analyst Price Targets 2026

7 analysts currently rate the Beyondspring stock: 6 recommend buying, 1 holding and 0 selling.

Beyondspring Analyst Price Targets 2026

Converted at the current exchange rate, the Beyondspring share trades at 0.62 EUR (0.72 USD).

The Beyondspring share (BYSI) is listed on 1 stock exchanges, including: NASDAQ (BYSI).

Beyondspring Inc is a biopharmaceutical company focused on researching and developing innovative cancer therapies. The company is headquartered in New York, USA, and has research and development facilities in the USA and China. Its business model is centered around identifying and developing cancer therapies that have the potential to improve the lives of patients worldwide. It particularly focuses on developing drugs for the treatment of blood and lymphatic system cancers, as well as those that counteract the side effects associated with chemotherapy. Beyondspring Inc's research and development activities are divided into two main areas: innovative cancer therapies and supportive care products. The company has several innovative cancer therapies in various stages of development, with its most advanced drug being Plinabulin. This drug is being studied for the treatment of various cancers such as lung, stomach, and pancreatic cancer. Plinabulin is a novel cytoprotective antineoplastic agent that is able to kill cancer cells while protecting healthy cells. It is intended to be used in combination with other cancer therapies such as chemotherapy and immunotherapy. Beyondspring Inc also offers a range of supportive care products under the brand BeyondCare. These products help reduce the side effects of cancer therapies and improve the well-being of cancer patients. They include mouthwashes, moisturizers, and other care products specifically designed for cancer patients. The products are made with natural ingredients only, are hypoallergenic, and free from harmful chemicals. In conclusion, Beyondspring Inc's business model is focused on researching, developing, and marketing innovative cancer therapies and supportive care products. The company is dedicated to developing safe and effective cancer therapies with the aim of improving the lives of cancer patients worldwide. With its wide range of products and services, it positions itself as a key player in the healthcare industry and contributes to improving the quality of life for cancer patients.

The revenue cannot currently be calculated for Beyondspring.

The profit cannot currently be calculated for Beyondspring.

The P/E ratio cannot be calculated for Beyondspring at the moment.

The P/S cannot be calculated for Beyondspring currently.

The Eulerpool Quality Score for Beyondspring is 2/10.

The ISIN of Beyondspring is KYG108301006. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Beyondspring is A2DNMQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Beyondspring is BYSI. The ticker symbol is used to trade Beyondspring shares on the stock exchange.

Beyondspring paid dividends every year for the past 0 years.

Beyondspring is assigned to the 'Health' sector.

The dividends of Beyondspring are distributed in USD.

All fundamentals and in-depth analysis of Beyondspring

Our stock analysis for Beyondspring stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beyondspring. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Beyondspring Stock
Beyondspring Revenue→
Beyondspring Stock
Beyondspring Net Income→
Beyondspring Stock
Beyondspring P/E→
Beyondspring Stock
Beyondspring P/S→
Beyondspring Stock
Beyondspring EBIT→
Beyondspring Stock
Beyondspring Dividend→
Beyondspring Stock
Beyondspring Directors Dealings→
Beyondspring Stock
Beyondspring Stocks→
Beyondspring Stock
Beyondspring Market capitalization→
Beyondspring Stock
Beyondspring Debt→
Beyondspring Stock
Beyondspring Liabilities→
Beyondspring Stock
Beyondspring Equity→
Beyondspring Stock
Beyondspring AAQS→
Beyondspring Stock
Beyondspring Employees→
Beyondspring Stock
Beyondspring ROE→
Beyondspring Stock
Beyondspring ROA→
Beyondspring Stock
Beyondspring ROCE→
Beyondspring Stock
Beyondspring News→
Beyondspring Stock
Beyondspring Analyst Price Targets→

Health Stocks

BG MedicineBeyond AirBGI Genomics CoBetterLife PharmaBGM GroupBetter TherapeuticsBharat Immunologicals and Biologicals CorporationBetta Pharmaceuticals CoBharat ParenteralsBeta BionicsBibbInstrumentsBeryl DrugsAll Stocks A–Z →